<DOC>
	<DOCNO>NCT00368797</DOCNO>
	<brief_summary>This study double-blind study evaluate efficacy safety NV1FGF , pCOR plasmid construct insert gene cod FGF compare placebo patient severe Peripheral Arterial Occlusive Disease , Fontaine 's stage IV . The efficacy assess complete heal least one ulcer treat limb , 25 week post-baseline secondary rate amputation death .</brief_summary>
	<brief_title>Efficacy Safety Study NV1FGF Patients With Severe Peripheral Artery Occlusive Disease</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Outpatients severe Peripheral Artery Occlusive Disease define Rutherford 's Grade III , category 5 6 , Fontaine 's stage IV . Trophic lesion sign heal ( reduction ulcer size depth ) least 2 week prior first study treatment administration ( Day 1 ) . Patients objective evidence peripheral vascular disease ( rest ankle pressure &lt; 70 mmHg and/or toe pressure &lt; 50 mmHg , and/or rest anklebrachial index ( ABI ) &lt; 0.4 and/or rest toebrachial index ( TBI ) &lt; 0.3 and/or metatarsal pulse volume record ( PVR ) flat barely pulsatile ) diseased limb two consecutive examination perform least 1 week apart . Demonstration documentation ( historical data older 6 month prior first study treatment administration ) total occlusion affect limb one iliac , superficial femoral , popliteal and/or one infrapopliteal artery assess angiography . Life expectancy &gt; 6 month first study treatment administration . Poor/not candidate revascularization ( patient suitable revascularization high risk failure/ amputation/ patient suitable revascularization ) . Previous current history malignant disease . Patients successful tumor resection radiochemotherapy 5 year prior inclusion study recurrence allow inclusion . Suspicion malignant disease ( abnormal X ray , positive . stool hemoccult , positive Prostate Specific Antigen , abnormal mammography , papanicolaou smear Class IV Class V characterization . Lower extremity surgery : bypass/angioplasty leg treat within 2 month prior first administration study treatment ( Day 1 ) . Active proliferative retinopathy . Buerger 's disease</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Gene Therapy</keyword>
	<keyword>PAOD</keyword>
	<keyword>CLI</keyword>
</DOC>